礼来制药和诺和诺德公司声称其GLP-1减肥药物能够减缓生物衰老1。两家公司的研究数据表明，服用这些药物的超重或糖尿病患者的生物年龄相比对照组减少约2至3年1，某些心脏蛋白衰老时钟甚至显示减缓幅度达4年1。诺和诺德全球项目负责人Nikolaj Roed表示患者生物年龄改善约"2至3年"1。
这些发现在科学界引起关注。加州大学洛杉矶分校教授Steve Horvath评价称"两年是一个相当强的效果"1。哈佛生物学家Vadim Gladyshev表示"在不健康人群中，它确实是抗衰老药物"1。诺和诺德对10052名患者进行了血液采样研究，其中一半服药，另一半使用安慰剂1。礼来则使用"表观遗传"时钟测量DNA积累的变化1。
礼来的替扎帕肽去年为公司带来超过360亿美元的收入1。美国ARPA-H机构已投入3800万美元资助德州研究，预计将在一两年内产生答案1。
Eli Lilly and Novo Nordisk have released research data suggesting their GLP-1 weight-loss medications may slow biological aging in patients.1 According to the companies' findings, overweight or diabetic patients taking these drugs showed improvements in biological age of approximately two to three years compared to control groups, with some cardiac protein aging clocks indicating a slowdown of up to four years.1
Nikolaj Roed, global head of programs at Novo Nordisk, stated that patients experienced biological age improvements of about "two to three years."1 UCLA professor Steve Horvath characterized this as "quite a strong result."1 Harvard biologist Vadim Gladyshev remarked that in unhealthy populations, the medication "really is an anti-aging drug."1 These observations have prompted scientists to speculate that GLP-1 drugs could represent a genuine life-extension therapy.
The commercial significance of these findings is substantial. Eli Lilly's tirzepatide generated over $36 billion in revenue for the company last year.1 Novo Nordisk conducted blood sampling across 10,052 patients, with half receiving the medication and half receiving placebo.1 Eli Lilly employed "epigenetic" clocks to measure changes in DNA accumulation.1 The U.S. ARPA-H agency has committed $38 million to fund research in Texas, with results expected within one to two years.1
评论
还没有评论，欢迎留下第一条。